Myelodysplastic syndromes.
A cure for MDS has yet to be found. The aim of therapy is to attempt to restore normal hematopoiesis and prevent evolution to acute leukemia. The major trend is supportive care. Blood counts and bone marrow aspirations are taken to evaluate the disease, and transfusions of blood products and antibiotics are given when necessary. A new encouraging modality of therapy is the use of hematopoietic growth factors to reverse cytopenias. As there is no curative treatment for MDS, the patient is likely to be offered investigational drugs either singly or in combination. Future trends in the treatment of MDS will be combinations of agents including biological agents with retinoic acid or vitamin D, low-dose Ara-C, the interferons, and colony-stimulating factors.
Yeomans
A C
AC
Harle
M T
MT
D000970:Antineoplastic Agents / Q000627:therapeutic use; D006801:Humans; D009190:Myelodysplastic Syndromes / Q000175:diagnosis / Q000188:drug therapy / Q000451:nursing*; D011379:Prognosis
D000970:Antineoplastic Agents